NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Corcept Therapeutics Inc. CORT
19 fiscal years on record · USD · FY2025 reported · SEC filings only
In brief
What this company does
Written from the business description in CORCEPT THERAPEUTICS INC's annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.
Growth
USD 761.4M
Revenue, FY2025 · full 19-year series below
Revenue $M
Net income $M
FY2025 · Revenue 761.4 · Net income 99.7
Compound annual growth
+23.7%
+16.6%
+31.2%
−0.6%
−1.2%
−2.0%
−0.7%
+73.7%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +16.6% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
13 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 5.9% · Net 13.1%
ROE
FY2025 · ROE 15.0%
Each USD of equity produced 15 cents of profit this year.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.8 | 0.7 | 0.5 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.2 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | · | · | 0.0 | · | · |
| Operating income $B | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| EBITDA $B | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| Income tax $B | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.1 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · |
| Net income $B | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | 0.1 | 0.2 | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · | · |
| EPS, diluted $ | 0.82 | 1.23 | 0.94 | 0.87 | 0.89 | 0.85 | 0.77 | 0.60 | 1.04 | 0.07 | −0.06 | −0.31 | −0.46 | −0.41 | −0.39 | −0.38 | −0.38 | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | 0.00 | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 15.0 | 23.8 | 21.0 | 23.1 | 25.0 | 23.7 | 29.1 | 32.3 | 111.1 | 27.2 | −84.8 | −356.0 | −111.1 | −78.8 | −115.4 | −119.8 | −103.4 | −126.8 | −78.5 |
| Shares out B | 0.11 | 0.11 | 0.10 | 0.11 | 0.11 | 0.12 | 0.11 | 0.12 | 0.11 | 0.11 | 0.11 | 0.10 | 0.10 | 0.10 | 0.08 | 0.07 | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 67 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 14 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2007